Hong Kong (HSI) Medical Equipment Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Medical Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 05 Aug 2026	HK$244.0b	HK$68.0b	HK$4.8b	15.2x	50.8x	3.6x
Fri, 03 Jul 2026	HK$219.6b	HK$67.7b	HK$4.8b	14.6x	45.9x	3.2x
Sun, 31 May 2026	HK$235.1b	HK$67.8b	HK$4.9b	16x	48x	3.5x
Tue, 28 Apr 2026	HK$249.4b	HK$66.1b	HK$2.5b	16.5x	99.8x	3.8x
Thu, 26 Mar 2026	HK$218.5b	HK$64.2b	HK$2.5b	15.4x	88.3x	3.4x
Sat, 21 Feb 2026	HK$246.9b	HK$63.7b	HK$2.4b	18x	105x	3.9x
Mon, 19 Jan 2026	HK$249.2b	HK$63.2b	HK$2.3b	21x	107.2x	3.9x
Wed, 17 Dec 2025	HK$191.4b	HK$62.3b	HK$2.5b	18.8x	77x	3.1x
Fri, 14 Nov 2025	HK$224.6b	HK$63.1b	HK$3.1b	21x	72.9x	3.6x
Sun, 12 Oct 2025	HK$228.1b	HK$62.8b	HK$3.0b	21.1x	77x	3.6x
Tue, 09 Sep 2025	HK$238.1b	HK$62.9b	HK$3.0b	22.6x	80.3x	3.8x
Thu, 07 Aug 2025	HK$229.9b	HK$61.9b	HK$3.2b	24.9x	71.5x	3.7x
Sat, 05 Jul 2025	HK$188.3b	HK$62.1b	HK$3.2b	21.5x	58.3x	3x
Mon, 02 Jun 2025	HK$171.1b	HK$61.8b	HK$3.2b	21.8x	53.4x	2.8x
Wed, 30 Apr 2025	HK$162.9b	HK$60.8b	HK$3.1b	21.9x	52x	2.7x
Fri, 28 Mar 2025	HK$165.4b	HK$59.5b	HK$1.3b	18.3x	131.8x	2.8x
Sun, 23 Feb 2025	HK$163.7b	HK$58.1b	HK$1.2b	18.1x	136.4x	2.8x
Tue, 21 Jan 2025	HK$133.6b	HK$57.8b	HK$1.2b	18.4x	114.2x	2.3x
Thu, 19 Dec 2024	HK$136.5b	HK$57.9b	HK$1.2b	17x	115.3x	2.4x
Sat, 16 Nov 2024	HK$132.5b	HK$58.3b	HK$1.2b	16.2x	109.2x	2.3x
Mon, 14 Oct 2024	HK$144.7b	HK$59.3b	HK$1.4b	13.8x	105.2x	2.4x
Wed, 11 Sep 2024	HK$115.2b	HK$59.0b	HK$1.3b	12.4x	90.1x	2x
Fri, 09 Aug 2024	HK$120.0b	HK$54.5b	-HK$1,017,711,749.73	12.2x	-117.9x	2.2x
Sun, 07 Jul 2024	HK$124.1b	HK$53.9b	-HK$1,099,407,474.63	12.6x	-112.8x	2.3x
Tue, 04 Jun 2024	HK$137.7b	HK$54.1b	-HK$1,095,824,529.44	13.1x	-125.6x	2.5x
Thu, 02 May 2024	HK$154.8b	HK$54.1b	-HK$1,093,945,754.74	15.7x	-141.5x	2.9x
Sat, 30 Mar 2024	HK$147.3b	HK$54.1b	-HK$1,426,745,114.47	13.1x	-103.3x	2.7x
Mon, 26 Feb 2024	HK$160.0b	HK$52.7b	-HK$1,116,753,596.51	12.7x	-143.3x	3x
Wed, 24 Jan 2024	HK$163.1b	HK$53.6b	-HK$2,350,430,966.00	12.4x	-69.4x	3x
Fri, 22 Dec 2023	HK$195.6b	HK$53.6b	-HK$2,343,458,731.00	14.7x	-83.5x	3.6x
Sun, 19 Nov 2023	HK$217.7b	HK$53.2b	-HK$2,338,413,317.00	18.1x	-93.1x	4.1x
Tue, 17 Oct 2023	HK$206.8b	HK$52.8b	-HK$2,343,493,488.00	20.6x	-88.2x	3.9x
Thu, 14 Sep 2023	HK$212.3b	HK$53.0b	-HK$2,344,517,431.00	16.5x	-90.6x	4x
Sat, 12 Aug 2023	HK$226.8b	HK$50.9b	-HK$3,933,660,878.00	18.5x	-57.7x	4.5x

Current Industry PE

Investors are optimistic on the Hong Kong Medical Equipment industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 50.8x which is higher than its 3-year average PE of 18.4x.

The 3-year average PS ratio of 3.1x is lower than the industry's current PS ratio of 3.6x.

Past Earnings Growth

Total earnings for the Medical Equipment industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 10% per year.
This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?


HK Market	0.83%
Healthcare	0.51%
Medical Equipment	9.75%
Medical Equipment	10.96%
Medical Supplies	5.09%

Industry PE

Investors are most optimistic about the Medical Equipment industry which is trading above its 3-year average PE ratio.

Analysts are expecting annual earnings growth of 50.3%, which is higher than its past year's earnings growth of 33.7% per year.

Investors are most pessimistic about the Medical Supplies industry, which is trading close to its 3-year average of 14.6x.

Forecasted Growth

Analysts are most optimistic on the Medical Equipment industry, expecting annual earnings growth of 50% over the next 5 years.
This is better than its past earnings growth rate of 34% per year.

In contrast, the Medical Supplies industry is expected to see its earnings grow by 14% per year over the next few years.

Company	Last Price	7D	1Y	Valuation
2526 Hangzhou Diagens Biotechnology	HK$376.60	52.1% +HK$11.5b	n/a	PS175.3x
2697 Guangdong True Health Medical Technology Development	HK$745.00	25.4% +HK$5.4b	n/a	PS1877.9x
6699 Angelalign Technology	HK$96.60	20.4% +HK$2.8b	69.0%	PE74x
2276 Shanghai Conant Optical	HK$33.76	14.6% +HK$2.1b	-24.4%	PE25.2x
2252 Shanghai MicroPort MedBot (Group)	HK$22.40	8.5% +HK$1.8b	6.1%	PS36.1x

Company

Last Price

Valuation

2526 Hangzhou Diagens Biotechnology

HK$376.60

52.1%
+HK$11.5b

n/a

PS175.3x

2697 Guangdong True Health Medical Technology Development

HK$745.00

25.4%
+HK$5.4b

n/a

PS1877.9x

6699 Angelalign Technology

HK$96.60

20.4%
+HK$2.8b

69.0%

PE74x

2276 Shanghai Conant Optical

HK$33.76

14.6%
+HK$2.1b

-24.4%

PE25.2x

2252 Shanghai MicroPort MedBot (Group)

HK$22.40

8.5%
+HK$1.8b

6.1%

PS36.1x

Shanghai Microport Medbot (Group) Co., Ltd. Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended 30 June 2026

Shanghai Microport Medbot (Group) Co., Ltd. provided preliminary consolidated earnings guidance for the six months ended 30 June 2026. For the period, the Board expects that the Company will turn from a net loss to recording a net profit during the Reporting Period, and the net profit is expected to be approximately RMB 28 million to RMB 40 million, as compared with a net loss of the Company of RMB 115 million for the six months ended 30 June 2025. This marks the first time the Company has achieved semi-annual profitability. The Company's turnaround from net loss to net profit during the Reporting Period was mainly due to the following factors: Substantial Growth in Revenue -- During the Reporting Period, the Group recorded a year-on-year revenue increase of approximately 200% to 230%. Toumai Laparoscopic Surgical Robot delivered robust growth in both domestic and overseas markets with a notable expansion in sales volume. In particular, Toumai's revenue from overseas markets grew by more than 450% year-on-year. Such growth was driven by widespread recognition of the product's technical competitiveness and clinical performance, coupled with the Group's effective synergy with MicroPort's overseas sales channels and resources, and both the depth and breadth of market coverage were expanded simultaneously. Significant Improvement of Gross Profit Margin -- During the Reporting Period, the Company's overall gross profit margin improved by more than 15 percentage points compared to the same period last year. This improvement was driven, on the one hand, by the dilution effect of fixed costs resulting from the expansion of production scale; on the other hand, the continuous optimisation of production processes led to an effective reduction in direct labour costs, while the phased implementation of cost-saving processes also contributed to a gradual reduction in material costs. Meanwhile, the continuous optimisation of product portfolio, particularly the rapid increase of revenue from high-margin consumables, has also driven the gross profit margin to steadily increase. Continuous Optimisation of Expense Control -- During the Reporting Period, the Company continued to achieve positive results in expense control and resource allocation. The ratio of operating expenses to revenue decreased significantly, further improving the overall operational efficiency.

Hong Kong (HSI) Medical Equipment Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Sisram Medical Ltd Launches Titanium Prime Treatment Concept In Hong Kong SAR

Investor sentiment deteriorates as stock falls 19%

Angelalign Technology Inc. to Report First Half, 2026 Results on Aug 31, 2026

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Shanghai Microport Medbot (Group) Co., Ltd. Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended 30 June 2026

Ak Medical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2026

Jenscare Scientific Co., Ltd. Completes First Batch Of Implantation In FDA IDE Pivotal Trial For LuX-Valve Plus

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

MicroPort Scientific Corporation Appoints Dr. Yingyao Chen as an Independent Non-executive Director

Guangdong True Health Medical Technology Development Co., Ltd. has completed an IPO in the amount of HKD 449.86514 million.

Upcoming dividend of CN¥0.23 per share

Upcoming dividend of HK$0.26 per share

Investor sentiment deteriorates as stock falls 15%